Related Experiment Video

Updated: Aug 4, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity

T E Massey1, R G Leeder, E Rafeiro

  • 1Department of Pharmacology and Toxicology, Queen's University, Kingston, ON, Canada.

Canadian Journal of Physiology and Pharmacology
|December 1, 1995
PubMed

Insights

Amiodarone is an effective anti-dysrhythmic drug but can cause fatal lung toxicity. Research reviews experimental models and mechanisms of amiodarone-induced pulmonary toxicity (AIPT), aiming for safer drugs and treatments.

Area of Science:

  • Pharmacology
  • Toxicology
  • Pulmonology

Background:

  • Amiodarone is a widely used anti-dysrhythmic medication.
  • Amiodarone-induced pulmonary toxicity (AIPT) is a severe, potentially fatal adverse effect.
  • Understanding AIPT mechanisms is crucial for patient safety.

Purpose of the Study:

  • To review experimental models for studying AIPT.
  • To summarize current knowledge on AIPT mechanisms.
  • To discuss future research directions for AIPT.

Main Methods:

  • Literature review of experimental models.
  • Synthesis of existing data on AIPT.
  • Discussion of proposed molecular and cellular pathways.

Main Results:

  • AIPT involves multiple potential mechanisms including phospholipidosis, altered calcium regulation, oxidative stress, and radical formation.
  • Cellular energy disruption and immune responses may also contribute to AIPT.
  • Various experimental models exist to study these processes.

Conclusions:

  • Elucidating AIPT mechanisms is key to developing safer anti-dysrhythmic drugs.
  • Understanding toxicity pathways may lead to effective prevention or treatment strategies for AIPT.
  • Further research is needed to fully understand and mitigate amiodarone's pulmonary risks.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model07:35

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Published on: December 10, 2021

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Pulmonary Edema II: Pathophysiology01:18

Pulmonary Edema II: Pathophysiology

Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...